KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer

Mamounas EP, Geyer CE, Huang CS, Mano MS, Loibl S, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, Digiovanna MP, Fasching P, Crown JP, Wuelfing P, Shao Z, Caremoli ER, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Von Minckwitz G (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Publisher: E M H SWISS MEDICAL PUBLISHERS LTD

City/Town: MUTTENZ

Pages Range: 13S-13S

Conference Proceedings Title: SWISS MEDICAL WEEKLY

Authors with CRIS profile

Involved external institutions

Evangelische Kliniken Gelsenkirchen Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Genentech Inc. United States (USA) (US) National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP) United States (USA) (US) Sana Klinikum Offenbach Germany (DE) GBG Forschungs GmbH (German Breast Group) Germany (DE) University of Montpellier / Université Montpellier France (FR) National Cancer Institute (NCI) United States (USA) (US) Azienda Ospedaliera Papa Giovanni XXIII Italy (IT) Roche China Ltd. China (CN) HELIOS Kliniken Germany (DE) National Taiwan University Hospital (NTUH) / 國立台灣大學醫學院附設醫院 Taiwan (TW) Hospital Universitario La Paz Spain (ES) F. Hoffmann-La Roche Ltd Switzerland (CH) Fudan University / 复旦大学 China (CN) Krankenhaus Jerusalem Germany (DE) Institute of Cancer of São Paulo Brazil (BR) Yale University United States (USA) (US)

How to cite

APA:

Mamounas, E.P., Geyer, C.E., Huang, C.-S., Mano, M.S., Loibl, S., Untch, M.,... Von Minckwitz, G. (2019). KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer. In SWISS MEDICAL WEEKLY (pp. 13S-13S). MUTTENZ: E M H SWISS MEDICAL PUBLISHERS LTD.

MLA:

Mamounas, Eleftherios P., et al. "KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer." Proceedings of the SWISS MEDICAL WEEKLY MUTTENZ: E M H SWISS MEDICAL PUBLISHERS LTD, 2019. 13S-13S.

BibTeX: Download